[CASE REPORT]

Endoscopic Mucosal Resection of Adenocarcinoma at the Minor Duodenal Papilla: A Case Report and Suggestions for the Optimal Treatment Strategy

Takao Sato¹, Ryota Sagami¹, Hidefumi Nishikiori¹, Hiroaki Tsuji¹, Keiji Sato², Tsutomu Daa³ and Kazunari Murakami⁴

Abstract:

We herein report an extremely rare case of adenocarcinoma of the minor duodenal papilla (MiDP) which was successfully treated by endoscopic mucosal resection (EMR). An asymptomatic 84-year-old man underwent upper gastrointestinal endoscopy, which revealed a slightly elevated lesion at the MiDP. The biopsy findings were suggestive of adenocarcinoma. Computed tomography, magnetic resonance images and endoscopic ultrasonography did not reveal pancreatic tumor infiltration nor any apparent distant metastases. Therefore, we treated the lesion using EMR with complete resection. No recurrence or metastasis has been detected at 13 months after EMR. Total resection of the MiDP can thus serve as a relatively safe and simple treatment.

Key words: adenocarcinoma, endoscopic mucosal resection, major duodenal papilla, minor duodenal papilla

(Intern Med Advance Publication) (DOI: 10.2169/internalmedicine.6404-20)

Introduction

The minor duodenal papilla (MiDP) is typically located in the second portion of the duodenum, proximal to the major duodenal papilla (MaDP) (1). It is an orifice to the accessory pancreatic duct from the dorsal pancreas and is recognized as a small elevation. Since the first case of MiDP adenocarcinoma was reported in 1998 (2), tumors of the MiDP have only rarely been reported. Most have been treated by surgical resection, however, a few cases were treated by endoscopic resection (3, 4). Endoscopic resection of MaDP tumors, via papillectomy, has already been established to some extent (5–7). However, there is no consensus on the optimal treatment for MiDP tumors. Recently, endoscopic resection of early-stage MiDP tumors has been considered an easy, minimally invasive, and diagnostic primary treatment prior to surgical resection. We herein report a case of MiDP adenocarcinoma which was completely resected endoscopically in order to provide suggestions for the optimal endoscopic treatment of MiDP tumors with support from a literature review.

Case Report

An asymptomatic 84-year-old Japanese man underwent upper gastrointestinal endoscopy for the follow-up of varices secondary to cirrhosis. The MiDP was reddish, slightly elevated, and measured 5 mm in diameter. It was located 2 cm proximal to the normal MaDP (Fig. 1). The biopsy specimen histopathologically indicated adenocarcinoma. All laboratory data, including tumor markers and pancreatic enzymes, were within the normal ranges. This lesion was not detected by any other imaging modality. Distant metastasis, dilatation of main pancreatic duct, and pancreatic divisum were not noted by abdominal computed tomography (CT) and magnetic resonance images. The tumor was considered to be a non-invasive lesion because of the image of a hy-
Figure 1. Imaging of the minor and major duodenal papilla. A: Upper gastrointestinal endoscopy revealed a reddish, slightly elevated lesion measuring 5 mm in diameter at the minor duodenal papilla. B: The major papilla of Vater was normal.

Figure 2. EUS detected a 14×9 mm homogeneous, hypoechogenic lesion in the submucosal layer with preservation of the muscularis propria (arrowheads).

Histopathologically, the MiDP specimen (measuring 7×6 mm in diameter) had an atypical epithelium on the surface of the mucosa, continuously elevated from the duodenal epithelium with increased chromatin and enlarged nuclei (Fig. 4). There was a proliferation of the atypical epithelium with formed solid parts, irregular gland duct structures, and conspicuous structural heteromorphism. The lesion was diagnosed to be moderately differentiated tubular adenocarcinoma measuring 4×4 mm in diameter which was limited to the mucosa, without invasion of the submucosa, accessory pancreatic duct, vascular or lymphovascular structures with negative margins of the vertical and lateral sides. An immunohistochemical examination revealed limited positive staining for MUC-2 and MUC-5AC, and negative staining for MUC-1 and MUC-6. Unfortunately, there were too few positive cells to discuss MUC expression. No local recurrence or metastasis has been detected by upper gastrointestinal endoscopy or CT 13 months after EMR.

Discussion

Characteristics of MiDP adenocarcinoma

Most MiDP tumors are reported to be adenomas (8-12), neuroendocrine tumors (13, 14), or rarely, ganglyocytic paragangliomas (15, 16). MiDP adenocarcinoma is extremely rare. We reviewed the PubMed database for articles written in English and published between 1998 and 2019 with the keywords adenocarcinoma and minor duodenal papilla. Thirteen reports about MiDP adenocarcinoma were found (2-4, 17-26). One of the reasons for so few reports on MiDP adenocarcinoma is the difficulty in early diagnosis (2, 25). MiDP is not carefully observed during upper gastrointestinal screening endoscopy and an MiDP tumor phylaxis of exposing the ulcer to gastric acid. The ENBPD tubes were removed after second-look endoscopy. The patient was discharged 10 days after EMR without any adverse events.

Histopathologically, the MiDP specimen (measuring 7×6 mm in diameter) had an atypical epithelium on the surface of the mucosa, continuously elevated from the duodenal epithelium with increased chromatin and enlarged nuclei (Fig. 4). There was a proliferation of the atypical epithelium with formed solid parts, irregular gland duct structures, and conspicuous structural heteromorphism. The lesion was diagnosed to be moderately differentiated tubular adenocarcinoma measuring 4×4 mm in diameter which was limited to the mucosa, without invasion of the submucosa, accessory pancreatic duct, vascular or lymphovascular structures with negative margins of the vertical and lateral sides. An immunohistochemical examination revealed limited positive staining for MUC-2 and MUC-5AC, and negative staining for MUC-1 and MUC-6. Unfortunately, there were too few positive cells to discuss MUC expression. No local recurrence or metastasis has been detected by upper gastrointestinal endoscopy or CT 13 months after EMR.

Discussion

Characteristics of MiDP adenocarcinoma

Most MiDP tumors are reported to be adenomas (8-12), neuroendocrine tumors (13, 14), or rarely, ganglyocytic paragangliomas (15, 16). MiDP adenocarcinoma is extremely rare. We reviewed the PubMed database for articles written in English and published between 1998 and 2019 with the keywords adenocarcinoma and minor duodenal papilla. Thirteen reports about MiDP adenocarcinoma were found (2-4, 17-26). One of the reasons for so few reports on MiDP adenocarcinoma is the difficulty in early diagnosis (2, 25). MiDP is not carefully observed during upper gastrointestinal screening endoscopy and an MiDP tumor phylaxis of exposing the ulcer to gastric acid. The ENBPD tubes were removed after second-look endoscopy. The patient was discharged 10 days after EMR without any adverse events.

Histopathologically, the MiDP specimen (measuring 7×6 mm in diameter) had an atypical epithelium on the surface of the mucosa, continuously elevated from the duodenal epithelium with increased chromatin and enlarged nuclei (Fig. 4). There was a proliferation of the atypical epithelium with formed solid parts, irregular gland duct structures, and conspicuous structural heteromorphism. The lesion was diagnosed to be moderately differentiated tubular adenocarcinoma measuring 4×4 mm in diameter which was limited to the mucosa, without invasion of the submucosa, accessory pancreatic duct, vascular or lymphovascular structures with negative margins of the vertical and lateral sides. An immunohistochemical examination revealed limited positive staining for MUC-2 and MUC-5AC, and negative staining for MUC-1 and MUC-6. Unfortunately, there were too few positive cells to discuss MUC expression. No local recurrence or metastasis has been detected by upper gastrointestinal endoscopy or CT 13 months after EMR.
Figure 3. Endoscopic treatment of the lesion of minor duodenal papilla. A: Side-view of the tumor. B: Snare polypectomy (EMR) of the tumor. C: Closure by clips after resection. D/E: Both endoscopic nasobiliary drainage tube (5Fr) and nasopancreatic drainage tube (4Fr) were inserted from the major duodenal papilla. F: Resected specimen.

Figure 4. The histopathological examination of the resected specimen (Hematoxylin and Eosin staining). There was moderately differentiated tubular adenocarcinoma within the mucosa of the minor duodenal papilla without infiltration submucosa, accessory pancreatic duct (arrow), vascular, or lymphovascular structures (magnification, A: ×4, B-D: ×20). Mild inflammatory cell infiltration with fibrosis (C) and fatty replacement (D) are seen in the submucosa.
has few clinical symptoms unless it obstructs the pancreatic duct flow with pancreas divisum, in which the drainage route of pancreatic juice generally becomes the MiDP and may cause pancreatitis-related symptoms at a relatively early stage when a tumor develops. Therefore, tumors are typically detected only in advanced stages when the origin of the tumor cannot be determined (2). In our case, the patient had neither any symptoms nor pancreas divisum. However, an abnormal MiDP was incidentally detected due to the observation of the duodenum in detail during varices screening.

Twenty-two cases of MiDP adenocarcinomas in 13 reports, as well as our case, are summarized in Table. The mean age was 69 years (range 50 to 84) and 13 patients were men. Mean tumor size was 21 mm (range 4 to 50). Eight patients (61.5%) were asymptomatic, whereas the remainder had either abdominal pain and/or jaundice. Four non-invasive carcinomas were incidentally identified by screening upper gastrointestinal endoscopy. There were no patients with familial adenomatous polyposis (FAP). Patients with FAP invariably develop duodenal adenomas and have a risk of papillary carcinoma (27), however, there have been no cases of MiDP carcinoma with FAP and the difference between FAP-complicated MiDP adenomas and sporadic adenomas has not been clarified (28). Most tumors were resected surgically, and only 3 cases with non-invasive carcinoma were managed using EMR. Additionally, 2 cases involved synchronous carcinomas of the MaDP and MiDP. Non-invasive carcinomas were smaller in diameter compared to invasive carcinoma at 10.5 vs. 23.8 mm, respectively (p=0.003). Lymph node metastasis was observed in only 2 cases with larger tumors. During the follow-up period (average, 42 months; range, 8-85 months), thirteen cases (68.4%) had no evidence of recurrence, and 3 cases died due to tumor recurrence.

On immunostaining in the previously reported cases of MiDP carcinomas, intestinal-type tumors tended to be positive for CK20, CDX2 and MUC2, whereas the pancreatabiliary-type tumors tended to stain with CK7, MUC1 (25, 29). Only one case of gastric-type carcinoma in adenoma of MiDP was reported to be stained with MUC-5 AC in the surface layer and MUC-6 in the deep layer (4).

**Diagnosis and treatment for MiDP adenocarcinoma**

A biopsy is necessary to make a preoperative diagnosis of adenocarcinoma. However, an endoscopic biopsy has limited accuracy in the diagnosis of MaDP tumors because it is difficult to rule out the presence of cancer in deeper layers (30, 31). Differentiating benign tumors from malignant ones, based on the size or endoscopic findings, is also difficult (24). The same may be expected in MiDP tumors. On the other hand, an accurate assessment of invasion depth is important to determine the optimal therapy.

Some reports suggested that evaluations of invasion by EUS had an accuracy rate of 63% to 92% in local extent of MaDP tumor progression (32-35), and similar results are obtained in MiDP tumors (4). In the present case, a 14×9 mm hypoechoic lesion was found in the submucosa by EUS, the cause of which was unclear from the resected specimen as well as previously reported case (4). In our case, fibrosis, mild inflammatory cell infiltration and fatty replacement may be induced by accessory pancreatic duct obstruction in submucosa histopathologically, and they may appear as a hypoechoic lesion in EUS. EUS is a highly accurate modality for staging ampullary tumors and for evaluating ductal involvement (34), however, there is also an opinion that a single layer of neoplastic cell extension is <20 μm thick and cannot be distinguished with clinical imaging (3). On the other hand, the EUS image obtained by the miniature ultrasonic probe with a high frequency (20 MHz) was reported to visualize more faithfully the histological findings of the excised specimen than the normal EUS image (36). Therefore, the ultrasonic diagnosis with a 20 MHz microprobe may be more effective and useful in diagnosing the progression of MiDP tumors. In clinical practice, however, there is no consensus regarding the preoperative diagnosis of MiDP tumors.

Recently, with the development of endoscopic tools and techniques, the indications for endoscopic papillectomy have been expanding and en block endoscopic resection for suspicious lesions of adenoma or non-invasive adenocarcinoma at MaDP is recommended as a diagnostic treatment (5-7), and that may apply to MiDP. However, in our review, surgical resection was selected as the primary therapy in most cases. Although a pancreaticoduodenectomy allows for the complete resection of the tumor, it is associated with a risk of various adverse events, including bleeding, pancreatic fistula, pulmonary complications, or delayed gastric emptying (37). Therefore, surgical treatment of the MiDP adenocarcinoma has been avoided in elderly patients, as well as those with various underlying diseases, such as in our case. However, many EMR procedures were performed for MiDP tumors without adenocarcinoma with good results (8, 11-14, 16, 38). If there are no apparent imaging findings of invasive cancer, total biopsy by EMR as a diagnostic treatment for MiDP tumors will be the good option prior to surgery. At our institutions, when MiDP or MaDP tumors have no apparent infiltration to the muscular layer or deeper site, we propose diagnostic treatment with EMR only in cases with a high risk for performing pancreaticoduodenectomy; nevertheless the careful selection of patients with appropriate criteria for EMR or surgery is required.

**Endoscopic resection for MiDP tumors**

In the endoscopic resection of MaDP tumors, local injection prior to resection or closure by clip after resection is not generally recommended. Meanwhile, pancreatic stent placement is recommended to prevent postoperative pancreatitis (39-42). Per our review, local injection was performed in most MiDP cases treated by EMR using glycerol (3), diluted epinephrine, or saline (4). In cases without pancreas divisum, local injection at the MiDP may not cause pancrea-
## Table. Previously Reported Cases of a Minor Papillary Adenocarcinoma.

| Case | Ref | Author     | Year | Age | Sex | Symptom                  | Treatment      | Macroscopic-type | Size (mm) | Major papilla | Pancreas division | Extent of Invasion | LN meta | Follow up (M) | Outcome |
|------|-----|------------|------|-----|-----|--------------------------|----------------|------------------|------------|---------------|-------------------|------------------|----------|---------------|---------|
| 1    | 2   | Yamao     | 1998 | 77  | M   | Transient abdominal pain | PPPD           | Elevated, central ulcer | 25         | Normal        | -                 | Pancreas         | ND       | 42            | DOO     |
| 2    | 17  | Kajiwara  | 2007 | 60  | M   | Transient abdominal pain | SSPPD          | Like villous adenoma with a stalk | 50         | Normal        | +                 | Pancreatic duct   | -        | ND NED        |         |
| 3    | 18  | Wakatsuki | 2008 | 70  | M   | None                     | PPPD           | Elevated, central ulcer | 11         | Normal        | -                 | Duodenal submucosa | -        | 32 NED       |         |
| 4    | 19  | Parthasarathy | 2008 | 60  | F   | Fever, jaundice          | PD             | Elevated, central ulcer | 15         | Carcinoma     | -                 | Unclear          | -        | 8 NED        |         |
| 5    | 20  | Matheus   | 2008 | 50  | F   | Abdominal pain, jaundice | PPPD           | Elevated          | 15         | Carcinoma     | ND                | Duodenal wall     | -        | 24 NED       |         |
| 6    | 21  | Takami    | 2011 | 81  | M   | None                     | SSPPD          | Elevated          | 20         | Normal        | -                 | Pancreas         | -        | ND NED        |         |
| 7    | 22  | Okuma     | 2011 | 76  | M   | None                     | PPPD           | Elevated          | 12         | Normal        | -                 | Duodenal submucosa | -        | 16 NED       |         |
| 8    | 23  | Zuiki     | 2011 | 69  | M   | Abdominal pain           | PSSD           | Elevated          | 18         | Normal        | -                 | Sphincter muscle  | -        | 32 NED       |         |
| 9    | 24  | Hoshino   | 2013 | 64  | F   | None                     | TP             | Elevated          | 15         | Normal        | -                 | Intramucosa      | -        | 48 NED       |         |
| 10   | 25  | Shia      | 2014 | 66  | M   | ND                       | Surgical resection | ND               | 30         | ND            | ND                | Pancreas         | -        | 75 DOD       |         |
| 11   |     |           |      |     |     | ND                       | Surgical resection | ND               | 18         | ND            | ND                | Duodenal wall     | -        | 17 DOU       |         |
| 12   |     |           |      |     |     | ND                       | Surgical resection | ND               | 12         | ND            | ND                | Duodenal wall     | -        | 60 DOD       |         |
| 13   |     |           |      |     |     | ND                       | Surgical resection | ND               | 40         | ND            | ND                | Pancreas         | -        | 85 DOD       |         |
| 14   |     |           |      |     |     | ND                       | Surgical resection | ND               | 22         | ND            | ND                | Pancreas         | -        | 84 DOD       |         |
| 15   |     |           |      |     |     | ND                       | Surgical resection | ND               | 12         | ND            | ND                | Pancreas         | -        | ND DOD       |         |
| 16   |     |           |      |     |     | ND                       | Surgical resection | ND               | 35         | ND            | ND                | Duodenal serosa   | -        | ND DOD       |         |
| 17   |     |           |      |     |     | ND                       | Surgical resection | ND               | 37         | ND            | ND                | Pancreas         | +        | ND DOD       |         |
| 18   |     |           |      |     |     | ND                       | Surgical resection | ND               | 44         | ND            | ND                | Pancreas         | +        | 51 NED       |         |
| 19   | 26  | Suzumura  | 2015 | 70  | M   | None                     | PPPD           | Elevated          | 12         | Normal        | -                 | Pancreas         | -        | 17 NED       |         |
| 20   | 3   | Matsui    | 2016 | 69  | F   | None                     | EMR            | Elevated          | 11         | Normal        | -                 | Intramucosa      | -        | 80 NED       |         |
| 21   | 4   | Kawasaki  | 2019 | 67  | F   | None                     | EMR            | Elevated          | 12         | Normal        | -                 | Intramucosa      | -        | 36 NED       |         |
| 22   |     | Our       | 2020 | 84  | M   | None                     | EMR            | Elevated          | 4          | Normal        | -                 | Intramucosa      | -        | 13 NED       |         |

ND: not described, DOO: died of other cause, NED: no evidence of disease, DOD: died of disease, DOU: died of unknown cause, PPPD: pylorus-preserving pancreaticoduodenectomy, PD: pancreaticoduodenectomy, SSPPD: subtotal stomach-preserving Pancreaticoduodenectomy, PSSD: pancreas sparing segmental duodenectomy, TP: transduodenal papillectomy, EMR: endoscopic mucosal resection.
Tumor of the minor duodenal papilla

CT, MRCP, EUS

Invasive

Non-invasive

elderly or with severe underlying disease

Surgical resection

Endoscopic resection

Pancreas divisum (+)

Pancreas divisum (-)

Local injection: unnecessary
Closure by clip: unnecessary
Stenting: necessary

Local injection: acceptable
Closure by clip: acceptable
Stenting: unnecessary

Figure 5. The established strategy for tumors at the minor duodenal papilla.

In previous reports, underwater EMR for superficial non-ampullary duodenal epithelial tumor was reported to be safe, even without the use of submucosal injection (43), however, the optimal treatment strategies for MaDP and MiDP tumors are unclear. The surrounding muscular construction of MiDP is less massive compared to that of the MaDP (44). In addition, the area lined by the pancreatic tissue under the MiDP may not wide compared to that of the MaDP. Therefore, the risk of perforation after resection of MiDP tumor may increase if the tumor is resected without submucosal injection (3). Although there is no consensus on whether local injection is needed, excessive local injection interfering the resection with sufficient vertical and horizontal margins by snaring should be avoided.

There are few reports which describe successfully treating the MiDP with pancreas divisum combined with pancreatic stenting (12, 45), therefore, it is difficult to discuss the usefulness of pancreatic stenting after resection of MiDP with pancreas divisum. In our case, ENBPD tubes were placed through the MaDP into the pancreatic and bile ducts after EMR. The insertion of ENBPD tubes was reported to be useful for the prevention of perforation when complete closure of the post- endoscopic submucosal dissection (ESD) mucosal defect was impossible (46). The MiDP can be structurally weaker than the MaDP as mention above, hence we considered that the post-EMR ulcers should be prevented from exposure to pancreatic and bile juice, which may cause delayed perforation or bleeding.

We recommend EMR for the management of MiDP adenocarcinomas (Fig. 5). If there is no pancreas divisum, then the tumors are expected to have a relatively low risk of pancreatitis due to EMR combined with submucosal injection. Additionally, closure of the ulcer by clips after EMR may be acceptable. If there is pancreas divisum, the tumors might be detected relatively secondary to pancreatic obstruction symptoms (3). In such cases, the occurrence of post-EMR pancreatitis should be carefully monitored, and accessory pancreatic duct stenting should be considered. Submucosal injection prior to EMR requires careful judgment because while it may reduce delayed bleeding or perforation (3), it may complicate snaring or stent placement through MiDP. We believe that endoscopic resection of MiDP tumors can be performed to treat not only benign tumors, but also early adenocarcinomas whose abdominal CT and EUS do not show any metastasis or infiltration to the dorsal pancreatic duct.

In conclusion, we herein described a rare case of MiDP adenocarcinoma which was successfully and safely resected by EMR. Endoscopic resection as a diagnostic treatment, as well as total biopsy, is a minimally invasive treatment alternative to surgery for non-invasive MiDP adenocarcinoma. Further research is needed to obtain consensus regarding the primary method for the diagnosis and treatment of MiDP tumors.

The authors state that they have no Conflict of Interest (COI).

Statement of Ethics

Takao Sato and the co-authors have no ethical conflicts to disclose.

Takao Sato - project principal investigator; drafting of the manuscript.

Ryota Sagami - critical revision of the manuscript for important intellectual content.

Hidefumi Nishikiori, Hiroaki Tsuji - assisted with data acquisition.

Keiji Sato - technical and material support.

Tsutomu Daa - pathological diagnosis.

Kazunari Murakami - study supervision.
References

1. Kamisawa T. Clinical significance of the minor duodenal papilla and accessory pancreatic duct. J Gastroenterol 39: 605-615, 2004.
2. Yamao K, Ohhashi K, Furukawa T, et al. Primary carcinoma of the duodenal minor papilla. Gastrointest Endosc 48: 634-636, 1998.
3. Matsui T, Matsubayashi H, Hotta K, Sasaki K, Ito H, Ono H. A case of carcinoma in an adenoma of the duodenal minor papilla successfully treated with endoscopic mucosal resection. Endosc Int Open 04: E252-E254, 2016.
4. Kawashima Y, Ogawa M, Yamao Y, et al. A Case of Endoscopic Mucosal Resection of Carcinoma in Adenoma at the Minor Duodenal Papilla. Case Rep Oncol 12: 354-363, 2019.
5. Poley JW, Campos S. Methods and outcome of the endoscopic treatment of ampullary tumors. Ther Adv Gastroenterol 13: 1-13, 2020.
6. Ardengh JC, Kemp R, Lima-Filho ER, Dos Santos JS. Endoscopic papillotomy: The limits of the indication, technique and results. World J Gastroenterol 7: 987-994, 2015.
7. Yamamoto K, Itoi T, Sofuni A, et al. Expanding the indication of endoscopic papillotomy for T1a ampullary carcinoma. Dig Endosc 31: 188-196, 2019.
8. Sugiyama M, Kimura W, Muto T, Yahagi N, Ichinose M, Miki K. Endoscopic resection of adenoma of the minor papilla. Hepatogastroenterology 46: 189-192, 1999.
9. Nakamura Y, Tajiri T, Uchida E, et al. Adenoma of the Minor Papilla associated with Pancreas Divisum. Hepatogastroenterology 54: 1841-1843, 2007.
10. Akatsu T, Aiura K, Takahashi S, Kameyama K, Kitajima M, Kitagawa Y. Recurrent Pancreatitis Caused by Ampullary Carcinoma and Minor Papilla Adenoma in Familial Polyposis: Report of a Case. Surg Today 38: 440-444, 2008.
11. Trevino JM, Wilcox CM, Varadarajulu S. Endoscopic resection of minor papilla adenomas (with video). Gastrointest Endosc 68: 383-386, 2008.
12. Kanamori A, Kumada T, Kiriyama S, et al. Endoscopic papillotomy of minor papilla adenoma associated with pancreas divisum. World J Gastroenterol 15: 1138-1140, 2008.
13. Itoi T, Sofuni A, Isotaka F, Tsuchiya T, Kurihara T, Moriyasu F. Endoscopic resection of carcinoid of the minor duodenal papilla. World J Gastroenterol 13: 3763-3764, 2007.
14. Seo YK, Choi JS. Endoscopic Papillotomy for Synchronous Major and Minor Duodenal Papilla Neuroendocrine Tumors. Korean J Gastroenterol 72: 217-221, 2018.
15. Nakamura T, Ozawa T, Kitagawa M, et al. Endoscopic resection of gangliocytic paranglioma of the minor duodenal papilla: case report and review. Gastrointest Endosc 55: 270-273, 2002.
16. Ko JK, Park DH, Hwang HS. A Case of Concurrent Ampullary Adenoma and Gangliocytic Paranglioma at the Minor Papilla Treated with Endoscopic Resection. Clin Endosc 52: 382-386, 2019.
17. Kajiwara M, Fujii S, Takahashi S, et al. Adenocarcinoma of the minor duodenal papilla with intraepithelial spread to the pancreatic duct. Virchows Arch 451: 1075-1081, 2007.
18. Wakatsuki T, Irisawa A, Takagi T, et al. Primary Adenocarcinoma of the Minor Duodenal Papilla. Jpn J Gastroenterol 49: 333-336, 2008.
19. Parthasarathy S, Pottakatt B, Yooita M, Reddy SN, Reddy KM. Synchronous Adenocarcinomas of the Papilla Major and Minor. JOP 9: 332-334, 2008.
20. Matheus AS, Jukemura J, Montagnini AL, Kunitake T, Patzina RA, da Cunha JE. Synchronous Adenocarcinoma of the Major and Minor Duodenal Papilla. J Gastrointest Surg 12: 1301-1303, 2008.
21. Takami K, Moriya T, Kamiga T, et al. Adenocarcinoma of the Minor Duodenal Papilla: Report of a Case. Case Rep Gastroenterol+ 5: 172-178, 2011.
22. Okuma T, Ozaki T, Abe S, et al. Adenocarcinoma of the Minor Duodenal Papilla: Report of a Case. Surg Today 41: 568-571, 2011.
23. Zuki T, Sata N, Sasanuma H, et al. Adenocarcinoma of the minor duodenal papilla treated with pancreas-sparing segmental duodenectomy: case report and review of the literature. Clin J Gastroenterol 4: 412-417, 2011.
24. Hoshino A, Nakamura Y, Suzuki H, et al. Adenocarcinoma of the Minor Duodenal Papilla: Report of a Case. J Nippon Med Sch 80: 165-170, 2013.
25. Shia J, Agaram NP, Olgac S, Cobanov B, Aday S, Klimstra DS. Adenocarcinoma of the minor duodenal papilla and its precursor lesions: a clinical and pathologic study. Am J Surg Pathol 38: 526-533, 2014.
26. Suzuki H, Kai S, Kuroda N, et al. Primary adenocarcinoma of the minor duodenal papilla with mass-forming chronic pancreatitis: report of a case. Surg Today 45: 506-510, 2015.
27. Spogelman AD, Williams CB, Talbot IC, Domizio P, Phillips RK. Upper gastrointestinal cancer in patients with familial adenomatous polyposis. Lancet 2: 783-785, 1989.
28. Hasebe O, Ochi Y, Hara E, et al. The Tumors of Duodenal Minor Papilla. Tan to Sui 36: 1257-1266, 2015.
29. Nomura S, Nakagawara H, Hirayama M, et al. Adenocarcinoma of Minor Duodenal Papilla Treated by Endoscopic Mucosal Resection. Gastroenterol Endosc 58: 1413-1419, 2016.
30. Harano M, Ryozawa S, Iwano H, Tabu K, Sen-yo M, Sakaiya I. Clinical impact of endoscopic papillotomy for benign-malignant borderline lesions of the major duodenal papilla. J Hepatobiliary Pancreat Sci 18: 190-194, 2011.
31. Yamaguchi K, Enjoji M, Kitamura K. Endoscopic biopsy has limited accuracy in diagnosis of ampullary tumors. Gastrointest Endosc 36: 588-592, 1990.
32. Itoh A, Goto H, Naito Y, Hirooka Y, Furukawa T, Hayakawa T. Intradural ultrasonography in diagnosing tumor extension of cancer of the papilla of Vater. Gastrointest Endosc 45: 251-260, 1997.
33. Menzel J, Hoepfner N, Sulikowski U, et al. Polypoid tumors of the major duodenal papilla: preoperative staging with intraductal US, EUS, and CT-a prospective, histopathologically controlled study. Gastrointest Endosc 49: 349-357, 1999.
34. Ito K, Fujita N, Noda Y, et al. Preoperative evaluation of ampullary neoplasm with EUS and transpapillary intraductal US: a prospective and histopathologically controlled study. Gastrointest Endosc 66: 740-747, 2007.
35. Okano N, Igarashi Y, Hara S, et al. Endosonographic preoperative evaluation for tumors of the ampulla of Vater using endoscopic ultrasonography and intraductal ultrasonography. Clin Endosc 47: 174-177, 2014.
36. Fujimoto M, Nakazawa S, Yamao K. Two Cases of Minor Papilla Tumors and Ultrasonic Diagnosis with 20MHz Microprobe. Gastroenterol Endosc 36: 2041-2049, 1994.
37. Karim SAM, Abdulla KS, Abdulkarim QH, Rahim FH. The outcomes and complications of pancreaticoduodenectomy (Whipple procedure): Cross sectional study. Int J Surg 52: 383-387, 2018.
38. Nakamura T, Ozawa T, Kitagawa M, et al. Endoscopic resection of gangliocytic paranglioma of the minor duodenal papilla: case report and review. Gastrointest Endosc 55: 270-273, 2002.
39. Ardengh JC, Kemp R, Lima-Filho ER, Dos Santos JS. Endoscopic papillotomy: The limits of the indication, technique and results. World J Gastroenterol 7: 987-994, 2005.
40. Hyun H, Lee TH, Park JS, et al. A prospective multicenter study of submucosal injection to improve endoscopic snare papillotomy for ampullary adenoma. Gastrointest Endosc 85: 746-755, 2017.
41. Chung KH, Lee SH, Choi JH, et al. Effect of submucosal injection in endoscopic papillotomy of ampullary tumor: Propensity-score matching analysis. United European Gastroenterol J 6: 576-585, 2018.
42. Wang Y, Qi M, Hao Y, Hong J. The efficacy of prophylactic pancreatic stents against complications of post-endoscopic papillectomy or endoscopic ampullectomy: a systematic review and meta-analysis. Ther Adv Gastroenterol 12: 1-12, 2019.
43. Yamasaki Y, Uedo N, Takeuchi Y, et al. Underwater endoscopic mucosal resection for superficial nonampullary duodenal adenomas. Endoscopy 50: 154-158, 2018.
44. Suda K. Histopathology of the minor duodenal papilla. Dig Surg 27: 137-139, 2010.
45. Loew BJ, Lukens FJ, Navarro F, Roy M, Mattia A, Howell DA. Successful Endoscopic Resection of a Gangliocytic Paraganglioma of the Minor Papilla in a Patient with Pancreas Divisum and Pancreatitis (With Video). Gastrointest Endosc 65: 547-550, 2007.
46. Fukuhara S, Kato M, Iwasaki E, et al. Management of perforation related to endoscopic submucosal dissection for superficial duodenal epithelial tumors. Gastrointest Endosc 91: 1129-1137, 2020.

The Internal Medicine is an Open Access journal distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. To view the details of this license, please visit (https://creativecommons.org/licenses/by-nc-nd/4.0/).